IL250990A0 - Materials for human care - Google Patents
Materials for human careInfo
- Publication number
- IL250990A0 IL250990A0 IL250990A IL25099017A IL250990A0 IL 250990 A0 IL250990 A0 IL 250990A0 IL 250990 A IL250990 A IL 250990A IL 25099017 A IL25099017 A IL 25099017A IL 250990 A0 IL250990 A0 IL 250990A0
- Authority
- IL
- Israel
- Prior art keywords
- therapeutic agents
- human therapeutic
- human
- agents
- therapeutic
- Prior art date
Links
- 239000003814 drug Substances 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/11—Aldehydes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462066686P | 2014-10-21 | 2014-10-21 | |
| US201562161090P | 2015-05-13 | 2015-05-13 | |
| US14/721,011 US9402834B2 (en) | 2014-10-21 | 2015-05-26 | Human therapeutic agents |
| US201562184051P | 2015-06-24 | 2015-06-24 | |
| PCT/US2015/055968 WO2016064676A1 (en) | 2014-10-21 | 2015-10-16 | Human therapeutic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL250990A0 true IL250990A0 (en) | 2017-04-30 |
Family
ID=55761352
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL250990A IL250990A0 (en) | 2014-10-21 | 2017-03-07 | Materials for human care |
Country Status (13)
| Country | Link |
|---|---|
| EP (2) | EP3188721B1 (OSRAM) |
| JP (1) | JP6937237B2 (OSRAM) |
| KR (1) | KR20170066425A (OSRAM) |
| CN (3) | CN115569136A (OSRAM) |
| AU (1) | AU2015336311B2 (OSRAM) |
| CA (1) | CA2955114C (OSRAM) |
| DK (1) | DK3188721T3 (OSRAM) |
| ES (1) | ES2744913T3 (OSRAM) |
| IL (1) | IL250990A0 (OSRAM) |
| MX (1) | MX2017002489A (OSRAM) |
| RU (1) | RU2017115885A (OSRAM) |
| TW (1) | TW201625230A (OSRAM) |
| WO (1) | WO2016064676A1 (OSRAM) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016181220A2 (en) * | 2015-05-13 | 2016-11-17 | Ions Pharmaceutical S.À R.L. | Therapeutic compositions and methods of use thereof |
| AU2019205944A1 (en) | 2018-01-05 | 2020-07-09 | Icahn School Of Medicine At Mount Sinai | Method of increasing proliferation of pancreatic beta cells, treatment method, and composition |
| US11246902B2 (en) | 2018-02-23 | 2022-02-15 | Ankh Life Sciences Limited | Nutritional supplement for mammals |
| EP3768267B1 (en) | 2018-03-20 | 2025-05-14 | Icahn School of Medicine at Mount Sinai | Beta-carboline derivatives as dyrk1a inhibitors for the treatment of e.g. diabetes |
| US10875859B2 (en) | 2018-04-13 | 2020-12-29 | Ankh Life Sciences Limited | Thymoquinone/harmaline and related reaction products |
| US11452715B2 (en) | 2018-04-13 | 2022-09-27 | Ankh Life Sciences Limited | Thymoquinone/harmaline and related reaction products |
| US11453664B2 (en) | 2018-04-13 | 2022-09-27 | Ankh Life Sciences Limited | Thymoquinone/harmaline and related reaction products |
| US11453665B2 (en) | 2018-04-13 | 2022-09-27 | Ankh Life Sciences Limited | Thymoquinone/harmaline and related reaction products |
| US10947253B2 (en) | 2019-08-05 | 2021-03-16 | Ankh Life Sciences Limited | Fused polycyclic dimers |
| US12419872B2 (en) | 2020-03-05 | 2025-09-23 | Ankh Life Sciences Limited | Low-temperature synthesis of thymoquinone and harmaline compounds |
| US12129265B2 (en) | 2020-07-21 | 2024-10-29 | Ankh Life Sciences Limited | Therapeutic agents and uses thereof |
| CN115916195A (zh) * | 2020-07-21 | 2023-04-04 | 安科生命科学有限公司 | 治疗剂及其用途 |
| JP2023080697A (ja) * | 2021-11-30 | 2023-06-09 | 株式会社渡辺オイスター研究所 | 転移性ヒト前立腺がん細胞の増殖抑制剤 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS54126731A (en) * | 1978-03-20 | 1979-10-02 | Rikagaku Kenkyusho | Carcinostatic agent |
| US7355081B2 (en) * | 2002-04-17 | 2008-04-08 | The University Of North Carolina At Chapel Hill | Curcumin analogues and uses thereof |
| JP2004075666A (ja) * | 2002-05-15 | 2004-03-11 | Keio Gijuku | 造血器腫瘍の治療薬、免疫抑制剤、およびｐ５３を標的分子とする分子標的治療薬 |
| CN100503607C (zh) * | 2003-06-02 | 2009-06-24 | 新疆华世丹药物研究有限责任公司 | 去氢骆驼蓬碱衍生物类化合物及其应用 |
| FR2869540B1 (fr) * | 2004-04-30 | 2008-05-16 | Centre Nat Rech Scient Cnrse | Compositions pharmaceutiques contenant des derives de b-carboline, et leur utilisation pour le traitement des cancers |
| CN100553628C (zh) * | 2005-08-25 | 2009-10-28 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 2-溴-异香兰素在制备抗癌和/或辐射、化疗增敏药物中的应用 |
| US8735154B2 (en) | 2006-10-30 | 2014-05-27 | The University Of Kansas | Templated islet cells and small islet cell clusters for diabetes treatment |
| WO2008150899A1 (en) * | 2007-05-29 | 2008-12-11 | Emory University | Combination therapies for treatment of cancer and inflammatory diseases |
| CN101669931B (zh) * | 2008-09-08 | 2012-07-04 | 北京鼎国昌盛生物技术有限责任公司 | 长效姜黄素衍生物在制备抗肿瘤症药物中的应用 |
| WO2010121007A1 (en) * | 2009-04-15 | 2010-10-21 | The Ohio State University Research Foundation | Curcumin analogs as dual jak2/stat3 inhibitors and methods of making and using the same |
| WO2011133795A2 (en) * | 2010-04-22 | 2011-10-27 | The Brigham And Women's Hospital, Inc. | Beta-carbolines as inhibitors of haspin and dyrk kinases |
| US20120058208A1 (en) * | 2010-09-04 | 2012-03-08 | Synthite Industries Ltd. | Synergistic Composition for Enhancing Bioavailability of Curcumin |
| JP2013540767A (ja) * | 2010-10-07 | 2013-11-07 | ザ ジェイ． デヴィッド グラッドストーン インスティテューツ | 免疫不全ウイルス転写を調節するための組成物および方法 |
| US8039025B1 (en) | 2010-10-15 | 2011-10-18 | Life Plus, LLC | Methods and dosage forms for the treatment of human cancers |
| WO2015006646A1 (en) * | 2013-07-11 | 2015-01-15 | Specialty Nutrition Group, Inc. | Compositions comprising hydroxytyrosol, curcumin, and/or astaxanthin and use thereof |
-
2015
- 2015-10-16 MX MX2017002489A patent/MX2017002489A/es unknown
- 2015-10-16 ES ES15853030T patent/ES2744913T3/es active Active
- 2015-10-16 EP EP15853030.3A patent/EP3188721B1/en active Active
- 2015-10-16 CN CN202210871857.5A patent/CN115569136A/zh active Pending
- 2015-10-16 EP EP17185821.0A patent/EP3275465B1/en active Active
- 2015-10-16 CN CN201911016462.1A patent/CN110772512A/zh active Pending
- 2015-10-16 WO PCT/US2015/055968 patent/WO2016064676A1/en not_active Ceased
- 2015-10-16 CA CA2955114A patent/CA2955114C/en active Active
- 2015-10-16 KR KR1020177009791A patent/KR20170066425A/ko not_active Withdrawn
- 2015-10-16 CN CN201580057827.9A patent/CN107106519B/zh active Active
- 2015-10-16 RU RU2017115885A patent/RU2017115885A/ru not_active Application Discontinuation
- 2015-10-16 AU AU2015336311A patent/AU2015336311B2/en active Active
- 2015-10-16 DK DK15853030.3T patent/DK3188721T3/da active
- 2015-10-16 JP JP2017522542A patent/JP6937237B2/ja active Active
- 2015-10-21 TW TW104134465A patent/TW201625230A/zh unknown
-
2017
- 2017-03-07 IL IL250990A patent/IL250990A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2015336311A1 (en) | 2017-02-09 |
| MX2017002489A (es) | 2017-09-13 |
| ES2744913T3 (es) | 2020-02-26 |
| EP3188721B1 (en) | 2019-06-12 |
| KR20170066425A (ko) | 2017-06-14 |
| AU2015336311A2 (en) | 2020-02-06 |
| CN107106519A (zh) | 2017-08-29 |
| CN110772512A (zh) | 2020-02-11 |
| JP2017531689A (ja) | 2017-10-26 |
| RU2017115885A (ru) | 2018-11-23 |
| AU2015336311B2 (en) | 2020-05-14 |
| EP3188721A4 (en) | 2018-05-02 |
| CA2955114A1 (en) | 2016-04-28 |
| EP3275465A1 (en) | 2018-01-31 |
| JP6937237B2 (ja) | 2021-09-22 |
| CA2955114C (en) | 2023-01-03 |
| WO2016064676A1 (en) | 2016-04-28 |
| BR112017006190A2 (pt) | 2017-12-26 |
| CN107106519B (zh) | 2023-01-24 |
| EP3275465B1 (en) | 2020-05-06 |
| CN115569136A (zh) | 2023-01-06 |
| TW201625230A (zh) | 2016-07-16 |
| DK3188721T3 (da) | 2019-08-12 |
| EP3188721A1 (en) | 2017-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL250685A0 (en) | Medicinal substance induces cytotoxicity | |
| SG10201912416QA (en) | Therapeutic agents | |
| SI3132034T1 (sl) | Zdravstveni pripomočki | |
| GB201403093D0 (en) | Therapeutic compounds and their use | |
| GB201509893D0 (en) | Therapeutic agents | |
| IL250990A0 (en) | Materials for human care | |
| GB201517263D0 (en) | Therapeutic agents | |
| GB201410816D0 (en) | Therapeutic agents | |
| GB201603104D0 (en) | Therapeutic agents | |
| GB201410216D0 (en) | Therapeutic | |
| GB201509885D0 (en) | Therapeutic agents | |
| GB201502412D0 (en) | Therapeutic use | |
| GB201410817D0 (en) | Therapeutic agents | |
| GB201608797D0 (en) | Therapeutic use | |
| GB201410815D0 (en) | Therapeutic agents | |
| GB201509888D0 (en) | Therapeutic agents | |
| GB201513299D0 (en) | Therapeutic agents | |
| GB201510637D0 (en) | Therapeutic | |
| GB201418809D0 (en) | Therapeutic agents and uses thereof | |
| GB201409653D0 (en) | Pyrrolobenzodiazepine therapeutic agents | |
| GB201521767D0 (en) | Therapeutic agents | |
| GB201517264D0 (en) | Therapeutic agents | |
| GB201506786D0 (en) | Therapeutic use | |
| GB201616563D0 (en) | Therapeutic agents | |
| GB201410334D0 (en) | Therapeutic |